English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut
牛牛新股君
joined discussion · May 6 07:38

IPO Pricing | Cofoe Healthcare debuts today with nearly 400 times subscription, priced at HKD 39.33 per share, with a 5% chance of receiving one lot

Futu News May 6th update, $COFOE MEDICAL (01187.HK)$ Announced the allocation results, with shares priced at HKD 39.33 each, issuing a total of 27 million shares, 100 shares per lot, and officially listing today.
On the previous trading day, Koifu Healthcare closed up 2.21% in the gray market at HKD 40.2 per share. With each lot consisting of 100 shares, excluding handling fees, one lot yielded a profit of HKD 87.
During the public offering phase, Koifu Healthcare received 399.08 times subscription coverage. The final number of shares offered to the public was 2.7 million shares, accounting for approximately 10% of the total shares available for subscription. A total of approximately 105,900 valid applications were received, with around 15,008 processed applications. The approximate percentage of successfully allocated shares in one-lot subscriptions compared to the total applied shares was 5%.
Additionally, during the international placement phase, Koifu Healthcare received 3.4 times subscription coverage. The final number of shares allocated internationally was 24.3 million, equivalent to 90% of the total shares available for distribution. Futu Information has compiled the relevant data in the following table.
Futu News May 6th update, $COFOE MEDICAL (01187.HK)$ Announced the allocation results, with shares priced at HKD 39.33 each, issuing a total of 27 million shares, 100 shares per lot, and officially listing today. In the last trading session, Cofoe Healthcare closed 2.21% higher in the grey market, at HKD 40.20 per share. For one lot of 100 shares, excluding handling fees, investors earned HKD 87 per lot. During the public offering phase, Cofoe Healthcare received subscriptions 399.08 times over, with the final number of shares allocated through the public offer being 2.7 million shares, representing approximately 10% of the total issuance. A total of about 105,900 valid applications were received, with around 15,008 processed applications. The allotment ratio for one lot was approximately 5% of the total applied-for shares. In addition, during the international placement phase, Cofoe Healthcare was subscribed 3.4 times over. The final number of shares allocated internationally was 24.3 million shares, accounting for 90% of the total issuance. Futu News has compiled the relevant data in the table below: Company Overview Cofoe Medical is a home medical device company in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. The global home medical device industry is highly competitive, particularly in sectors like home rehabilitation aids, home respiratory support products, and home medical care consumables. The company offers a product portfolio covering more than 200 products and tens of thousands of SKUs...
Futu News May 6th update, $COFOE MEDICAL (01187.HK)$ Announced the allocation results, with shares priced at HKD 39.33 each, issuing a total of 27 million shares, 100 shares per lot, and officially listing today. In the last trading session, Cofoe Healthcare closed 2.21% higher in the grey market, at HKD 40.20 per share. For one lot of 100 shares, excluding handling fees, investors earned HKD 87 per lot. During the public offering phase, Cofoe Healthcare received subscriptions 399.08 times over, with the final number of shares allocated through the public offer being 2.7 million shares, representing approximately 10% of the total issuance. A total of about 105,900 valid applications were received, with around 15,008 processed applications. The allotment ratio for one lot was approximately 5% of the total applied-for shares. In addition, during the international placement phase, Cofoe Healthcare was subscribed 3.4 times over. The final number of shares allocated internationally was 24.3 million shares, accounting for 90% of the total issuance. Futu News has compiled the relevant data in the table below: Company Overview Cofoe Medical is a home medical device company in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. The global home medical device industry is highly competitive, particularly in sectors like home rehabilitation aids, home respiratory support products, and home medical care consumables. The company offers a product portfolio covering more than 200 products and tens of thousands of SKUs...
Company Overview
Cofoe Medical is a home medical device company in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. The global home medical device industry is highly competitive, particularly in sectors like home rehabilitation aids, home respiratory support products, and home medical care consumables.
With a leading product portfolio that includes over 200 types of products and tens of thousands of product specifications, Cofoe Medical can effectively meet the needs of family members across different age groups. Furthermore, the company's proven track record demonstrates its ability to win consumer trust, making it the preferred supplier for evolving home care needs throughout various stages of life. Since its inception, the company has been committed to building and improving its sales network, which it views as a key pillar of business success, as convenience and efficient accessibility are among the core demands of consumers and patients.
Financial Summary
For the fiscal years ended December 31, 2023, 2024, and 2025, Cofoe Healthcare's revenues were RMB 2,853.7 million, RMB 2,982.9 million, and RMB 3,387.5 million, respectively. The company's gross profits in 2023, 2024, and 2025 were RMB 1,172.6 million, RMB 1,508.7 million, and RMB 1,751.6 million, respectively. The company's annual profit increased from RMB 252.9 million in 2023 by RMB 59.4 million to RMB 312.3 million in 2024, and further rose from RMB 312.3 million in 2024 by RMB 58.0 million to RMB 370.3 million in 2025.
Source: Prospectus
Source: Prospectus
Use of Proceeds
In terms of fundraising purposes, Koifu Healthcare expects net proceeds from the global offering to amount to approximately HKD 1.007 billion (based on an offer price of HKD 39.33). According to the prospectus, Koifu Healthcare intends to allocate the proceeds from the global offering for the following purposes.
Approximately 30% will be used for global expansion; around 30% will be allocated for the company's ongoing product research and development and technological innovation, including its artificial intelligence and Internet of Things applications; about 20% will be directed toward expanding the company’s domestic sales channels and distribution networks; roughly 10% will be used for brand promotion and marketing activities; and approximately 10% will be reserved for working capital and general corporate purposes.
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu News May 6th update, $COFOE MEDICAL (01187.HK)$ Announced the allocation results, with shares priced at HKD 39.33 each, issuing a total of 27 million shares, 100 shares per lot, and officially listing today. In the last trading session, Cofoe Healthcare closed 2.21% higher in the grey market, at HKD 40.20 per share. For one lot of 100 shares, excluding handling fees, investors earned HKD 87 per lot. During the public offering phase, Cofoe Healthcare received subscriptions 399.08 times over, with the final number of shares allocated through the public offer being 2.7 million shares, representing approximately 10% of the total issuance. A total of about 105,900 valid applications were received, with around 15,008 processed applications. The allotment ratio for one lot was approximately 5% of the total applied-for shares. In addition, during the international placement phase, Cofoe Healthcare was subscribed 3.4 times over. The final number of shares allocated internationally was 24.3 million shares, accounting for 90% of the total issuance. Futu News has compiled the relevant data in the table below: Company Overview Cofoe Medical is a home medical device company in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. The global home medical device industry is highly competitive, particularly in sectors like home rehabilitation aids, home respiratory support products, and home medical care consumables. The company offers a product portfolio covering more than 200 products and tens of thousands of SKUs...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
3
Respect
1
81K Views
Report
Comments (4)
Write a Comment...
4
4
14